As more novel ophthalmic drugs and devices become available under the CMS “pass-through”designation, practices should be proactive in embracing these products.
Patti Barkey, COE, OCS
Advertisement
Articles by Patti Barkey, COE, OCS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5